{"page_content": "2020 CORPORATE SOCIAL RESPONSIBILITY REPORT8\nABOUT SERVE TRANSFORM ADVANCE REDEFINE ETHICS & COMPLIANCE REPORTING INDEX   Dear Communities\nBOSTON\nBOGARTDUBLIN\nATHLONE\nNEW HAVENZURICH\nTOKYOPRODUCT THERAPEUTIC AREA APPROVED INDICATION\nHematology\nHematology/NephrologyParoxysmal Nocturnal Hemoglobinuria (PNH)\nAtypical Hemolytic Uremic Syndrome (aHUS)\nHematology\nHematology/Nephrology\nNeurology\nNeurologyParoxysmal Nocturnal Hemoglobinuria (PNH)\nAtypical Hemolytic Uremic Syndrome (aHUS)\nGeneralized Myasthenia Gravis (gMG)\nNeuromyelitis Optica Spectrum Disorder (NMOSD)\nMetabolic disorders Hypophosphatasia (HPP)\nMetabolic disorders Lysosomal Acid Lipase Deficiency (LAL-D)\nAcute careFactor Xa (FXa) inhibitor-related uncontrolled  \nor life-threatening bleeds\n\u00ae\nFor more information on the rare diseases and devastating conditions we treat, please visit our website.LOCATIONS WHERE   \nPRIMARY OPERATIONS   \nARE CONDUCTED  \n \u2219Boston, Massachusetts, U.S.: Corporate \nheadquarters \n \u2219New Haven, Connecticut, U.S.: R&D Center  \nof Excellence \n \u2219Bogart, Georgia, U.S.: Commercial operations, \nR&D manufacturing \n \u2219Dublin, Ireland: Global supply chain, \ndistribution, R&D manufacturing, quality, \nadministration offices \n \u2219Athlone, Ireland: Commercial operations,  \nR&D manufacturing \n \u2219Zurich, Switzerland: International headquarters \n \u2219Tokyo, Japan: Regional offices ", "metadata": {"source": "NASDAQ_ALXN_2020.pdf", "page": 7, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}